From Prediction

to Proof:

Accelerating

Safer Biologics

Get Started
Who We Are

Fearless Science.

EpiVax partners with biologic and vaccine developers to manage immunogenicity risk throughout the product lifecycle. We leverage deep scientific expertise to develop and apply industry leading in silico analyses and in vitro approaches to generate actionable immunogenicity data. These insights help our partners reduce uncertainty, mitigate risks, and use resources more efficiently while building regulatory-ready strategies for safer, more effective therapies.

Learn More

13M+

sequences analyzed

18

of the 20 top pharmaceutical companies served

500+

industry, agency, & academic collaborators

28

years experience

240+

peer-reviewed publications
Highlights

“We’ve worked with EpiVax on several projects over the past few years, and it’s always been a positive experience. For our most recent program, they provided both in silico and in vitro immunogenicity assessments and gave us helpful scientific guidance along the way to regulatory approval.”

-Associate Director, Regulatory Affairs, Amneal Pharmaceuticals

“The interactions with EpiVax were on a different level. On one side we have specific projects, on the other side, we had the possibility to train our people in the area of interest. Our scientists consistently benefit from these interactions, including webinars and on-site visits. All EpiVax people we have been exposed to are not only at a high scientific level but also able to establish good personal relationships.”

 

– Walter Cabri, Senior Vice President API I&D, Fresenius Kabi

 “EpiVax is an excellent company to work with. Their services were flexible to match our needs and communications were always prompt.”

 

– Chris Bai, CEO, AmbioPharm, Inc.

“EpiVax’s immunogenicity analysis of our candidate is of great value to us and was well received! This was a very straightforward and fruitful collaboration and we’re very content.”

 

– Dr. Katja Wosikowski, TargED Biopharmaceuticals B.V.

“EpiVax scientists were very responsive to our needs. They provided important insight into the project and delivered a comprehensive and articulate report.”

 

– Carl Spana, President & CEO, Palatin Technologies

“We are very pleased with the detail-oriented scientific reports, timeliness, transparency, and accommodating nature of the EpiVax team. We can always count on the EpiVax team when we need them.”

 

– Simrat Singh, President, AmbioPharm, Inc. 

“The EpiVax analysis was helpful in that it formed part of the due diligence package presented to potential partners/investors in 2022. As a result, [COMPANY] was acquired and our lead molecule that EpiVax analyzed is in pre-clinical development. We have completed GMP manufacture, with IND submission planned in 2025.”

 

– Consultant & Former CSO, British Biomedical Company

“I couldn’t be more pleased with the results and the quality of EpiVax reporting. I look forward to continuing to work together.”

 

– Product Development Manager, U.S. Pharmaceutical Company

“The report is very good and beneficial for our work. We have found EpiVax’s science to be very highly sophisticated and have learned a great deal from our discussions. We are deeply grateful.”

 

– Assistant General Manager Vaccine & Biomedical Research Dept., Japanese Biomedical Company

Get in touch!

Provide your information to be connected with our Business Development team, who will promptly provide you more information and identify the right EpiVax scientists to continue the conversation.